TriSalus Life Sciences (NASDAQ:TLSI) Posts Earnings Results, Meets Estimates

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) released its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35), Zacks reports. The business had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.12 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Price Performance

Shares of TLSI traded down $0.07 during midday trading on Monday, hitting $5.55. 24,879 shares of the company traded hands, compared to its average volume of 42,895. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a market cap of $169.24 million, a P/E ratio of -2.23 and a beta of 0.48. The stock has a 50-day moving average of $5.40 and a 200-day moving average of $4.73.

Insider Activity

In other news, CFO James Emmett Young purchased 6,000 shares of the firm's stock in a transaction dated Wednesday, February 5th. The shares were purchased at an average price of $5.65 per share, with a total value of $33,900.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. This trade represents a 25.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Sean Murphy acquired 15,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.31 per share, with a total value of $79,650.00. Following the purchase, the insider now directly owns 182,732 shares of the company's stock, valued at $970,306.92. This trade represents a 8.94 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 54,856 shares of company stock worth $294,608. 32.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on TLSI. Roth Mkm reiterated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They set a "buy" rating and a $10.00 price target for the company. Finally, Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $11.56.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.